Influence of Tetrachlorodecaoxide (Ryoxon®) on the Development of Leukemia after Total-Body Gamma-Irradiation

Abstract

The effect of tetrachlorodecaoxide (TCDO) treatment after total-body irradiation (TBI) with γ-rays (single dose, about LD 50) on the development of radiation-induced leukemia was tested in rats. TCDO was applied intravenously from day 4 through day 11. The control group was exposed to the same dosage of X-rays (TBI), but received physiological saline solution instead of TCDO. Compared to the control group, TCDO therapy initially markedly increased the survival rate: 72 versus 44% (6 months after TBI) and 36 versus 20% (1-year survival rate). The overall survival, however, was not significantly prolonged. TBI caused leukemia in 36% of the rats in the irradiation control group without TCDO treatment, however, none of 24 rats treated with TCDO after X-ray exposure developed leukemia. Since in this study TCDO was only administered for 8 days during the acute phase of radiation syndrome, we suppose that additional TCDO treatment at various times later on would lead to even better results.

WF10 Stimulates NK Cell Cytotoxicity by Increasing LFA‐1‐Mediated Adhesion to Tumor Cells

“…WF10 was shown to inhibit the development and promotion of leukemia in animal models [11, 12]. The role of oxidative species in cancer is complex and has been extensively studied in the last decades.…”

“…WF10 is known to have various immunological effects by stimulating innate immune functions, while inhibiting adaptive immune functions [10]. In contrast to control animals, sublethally irradiated rats treated with WF10 developed significantly less hematological or solid tumors than controls [11, 12]. This antitumor effect of WF10 could be explained by stimulating the innate natural cytotoxicity against tumors.…”